Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides has announced the approval of two abbreviated new drug applications for dexamethasone sodium phosphate injection USP, 4mg (base)/mL in 1mL, 5mL, and 30mL vials, and dexamethasone sodium phosphate injection USP, 10mg (base)/mL in 10mL vials.
Subscribe to our email newsletter
Dexamethasone sodium phosphate injection is indicated to treat various conditions such as endocrine disorders, arthritis, blood disorders, dermatologic diseases, severe allergic reactions, eye diseases, certain cancers, gastrointestinal diseases and respiratory diseases.
Akorn-Strides is a joint venture formed in 2005 by Akorn and Strides Arcolab. The primary mission of the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “We are excited to announce these two ANDA product approvals for dexamethasone sodium phosphate injection.”